Extended Cycle Combined Hormonal Contraception

Obstetrics and Gynecology Clinics of North America

Volumn 34, Issue 1, 2007, Pages 43-55

  Steinauer, Jody ^a   Autry, Amy M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GESTAGEN; GESTODENE; PLACEBO;

BIRTH CONTROL; BLEEDING; BONE DENSITY; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEALTH SERVICE; HORMONAL CONTRACEPTION; HUMAN; MENSTRUATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SPOTTING; UNITED STATES; UNPLANNED PREGNANCY; WITHDRAWAL BLEEDING;

CONTRACEPTIVES, ORAL, COMBINED; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MENSTRUAL CYCLE; MENSTRUATION; TIME FACTORS;

EID: 34247490173     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ogc.2007.01.001     Document Type: Review

References (41)

1. Jones R.K., Darroch J.E., and Henshaw S.K. Contraceptive use among U.S. women having abortions in 2000-2001. Perspect Sex Reprod Health 34 6 (2002) 294-303
2. Rako S. No more periods?: the risks of menstrual suppression and other cutting-edge issues about hormones and women's health (2003), Harmony Books, New York
3. Kiechl S., Willeit J., Egger G., et al. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation 96 (1997) 3300-3307
4. Sullivan J.L. The iron paradigm of ischemic heart disease. Am Heart J 117 (1989) 1177-1188
5. Coutinho E.M., and Segal J.S. Is menstruation obsolete? (1999), Oxford University Press, New York
6. den Tonkelaar I., and Oddens B.J. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 59 (1999) 357-362
7. Glasier A.F., Smith K.B., van der Spuy Z.M., et al. Amenorrhea associated with contraception-an international study on acceptability. Contraception 67 (2003) 1-8
8. Andrist L.C., Arias R.D., Nucatola D., et al. Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception 70 (2004) 359-363
9. Sulak P.J., Buckley T., and Kuehl T.J. Attitudes and prescribing preferences of health care professionals in the United States regarding use of extended-cycle oral contraceptives. Contraception 73 (2006) 41-45
10. Cote I., Jacobs P., and Cumming D. Work loss associated with increased menstrual loss in the United States. Obstet Gynecol 100 (2002) 683-687
11. Baerwald A.R., Olatunbosun O.A., and Pierson R.A. Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. Contraception 70 (2004) 371-377
12. Sullivan H, Furniss H, Spona J, et al. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity. Fertil Steril 1999;72:115-20.
13. Spona J., Elstein M., Feichtinger W., et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 54 (1996) 71-77
14. Bachman G., Sulak P., Sampson-Landers C., et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 mcg ethinylestradiol and 3 mg drospirenone. Contraception 70 (2004) 191-198
15. Endrikat J., Cronin M., Gerlinger C., et al. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel. Contraception 64 (2001) 201-207
16. Anderson F.D., and Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 68 (2003) 89-96
17. Anderson F.D., Gibbons W., and Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 73 (2006) 229-234
18. Miller L., and Notter K. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol 98 (2001) 771-778
19. Anderson F., Gibbins W., and Portman D. Long-term safety of an extended-cycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial. Am J Obstet Gynecol 196 (2006) 92-96
20. Miller L., and Hughes J.P. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 101 (2003) 653-661
21. Kwiecien M., Edelman A., Nichols M.D., et al. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception 67 (2003) 9-13
22. Sulak P.J., Kuehl T.J., Coffee A., et al. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. Am J Obstet Gynecol 195 (2006) 935-941
23. Foidart J.M., Sulak P.J., Schellschmidt I., et al. The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days. Contraception 73 (2006) 34-40
24. Edelman A.B., Gallo M.F., Jensen J.T., et al. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 3 (2005) CD004695
25. Coutinho E.M., O'Dwyer E., Barbosa I.C., et al. Comparative study on intermittent versus continuous use of a contraceptive pill administered by vaginal route. Contraception 51 (1995) 355-358
26. Miller L., Verhoeven C.H., and Hout J. Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet Gynecol 106 (2005) 473-482
27. Stewart F.H., Kaunitz A.M., Laguardia K.D., et al. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Obstet Gynecol 105 (2005) 1389-1396
28. van den Heuvel M.W., van Bragt A.J., Alnabawey A.K., et al. Comparison of ethinyl estradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch, and an oral contraceptive. Contraception 72 3 (2005) 168-174
29. Vercellini P., Frontino G., De Giorgi O., et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 80 (2003) 560-563
30. Coffee A.L., Kuehl T.J., Willis S., et al. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol 5 (2006) 1311-1319
31. Sulak P.J., Scow R.D., Preece C., et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 95 (2000) 261-266
32. Sillem M., Schneidereit R., Heithecker R., et al. Use of an oral contraceptive containing drospirenone in an extended regimen. Eur J Contracept Reprod Health Care 8 (2003) 162-169
33. LaGuardia K.D., Fisher A.C., Bainbridge J.D., et al. Suppression of estrogen-withdrawal headache with extended transdermal contraception. Fertil Steril 83 (2005) 1875-1877
34. Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA 257 6 (1987) 796-800
35. Anderson F.D., Hait H., Hsiu J., et al. Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen. Contraception 71 (2005) 55-59
36. Bracken M.B. Oral contraception and congenital malformations in offspring: a review and meta-analysis of the prospective studies. Obstet Gynecol 76 (1990) 552-557
37. Berenson A.B., Radecki C.M., Grady J.J., et al. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol 98 (2001) 576-582
38. Cromer B.A., Blair J.M., Mahan J.D., et al. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 129 (1996) 671-676
39. Burkman R., Schlesselman J.J., and Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol 190 (2004) S5-S22
40. Collaborative Group on Hormonal Factors in Breast Cancer. ICRF Cancer Epidemiology Unit, Radliff Infirmary, Oxford UK. Lancet 347 9017 (1996) 1713-1727
41. Endrikat J., Klipping C., Gerlinger C., et al. A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 30 microg ethinyl estradiol and 75 microg gestodene on hemostatic variables, lipids, and carbohydrate metabolism. Contraception 64 (2001) 235-241